Kontrolleret, klinisk afprøvning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterundersøgelse. The Scandinavian Isoprinosine Study Group.:

S Thorsen; C Pedersen; E Sandström; C S Petersen; G Norkrans; J Gerstoft; A Karlsson; K C Christensen; C Håkansson; P O Pehrson

Kontrolleret, klinisk afprøvning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterundersøgelse. The Scandinavian Isoprinosine Study Group.

S Thorsen, C Pedersen, E Sandström, C S Petersen, G Norkrans, J Gerstoft, A Karlsson, K C Christensen, C Håkansson, P O Pehrson

Infektionsmedicinsk Afdeling

1 Citationer (Scopus)

Abstract

The safety and efficacy of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported separately. Of 866 HIV-seropositive individuals randomized, 832 were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS. Within 48 weeks, 10/412 patients (2.4%) assigned isoprinosine and 27/420 (6.4%) assigned placebo progressed to AIDS (p = 0.005; odds ratio: 2.8, 95% CI: 1.3-6.2). Intention-to-treat analysis showed identical results. No severe adverse reactions or toxicities were observed. We conclude that HIV-infected individuals without AIDS may be safely and effectively treated with isoprinosine.

Bidragets oversatte titel	[Controlled, clinical trial of isoprinosine administration to HIV-infected patients. Results of a Danish/Swedish multicenter study. The Scandinavian Isoprinosine Study Group]
Originalsprog	Dansk
Tidsskrift	Ugeskr Laeger
Vol/bind	156
Udgave nummer	22
Sider (fra-til)	3314-3318
Antal sider	5
Status	Udgivet - 1994

Adgang til dokumentet

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7520643&query_hl=141

Citationsformater

Thorsen, S., Pedersen, C., Sandström, E., Petersen, C. S., Norkrans, G., Gerstoft, J., Karlsson, A., Christensen, K. C., Håkansson, C., & Pehrson, P. O. (1994). Kontrolleret, klinisk afprøvning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterundersøgelse. The Scandinavian Isoprinosine Study Group. Ugeskr Laeger, 156(22), 3314-3318. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7520643&query_hl=141

Thorsen, S, Pedersen, C, Sandström, E, Petersen, CS, Norkrans, G, Gerstoft, J, Karlsson, A, Christensen, KC, Håkansson, C & Pehrson, PO 1994, 'Kontrolleret, klinisk afprøvning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterundersøgelse. The Scandinavian Isoprinosine Study Group.', Ugeskr Laeger, bind 156, nr. 22, s. 3314-3318. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7520643&query_hl=141>

@article{8fc083011c424d86a312efce15c9e2f4,

title = "Kontrolleret, klinisk afpr{\o}vning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterunders{\o}gelse. The Scandinavian Isoprinosine Study Group.",

abstract = "The safety and efficacy of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported separately. Of 866 HIV-seropositive individuals randomized, 832 were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS. Within 48 weeks, 10/412 patients (2.4%) assigned isoprinosine and 27/420 (6.4%) assigned placebo progressed to AIDS (p = 0.005; odds ratio: 2.8, 95% CI: 1.3-6.2). Intention-to-treat analysis showed identical results. No severe adverse reactions or toxicities were observed. We conclude that HIV-infected individuals without AIDS may be safely and effectively treated with isoprinosine.",

author = "S Thorsen and C Pedersen and E Sandstr{\"o}m and Petersen, {C S} and G Norkrans and J Gerstoft and A Karlsson and Christensen, {K C} and C H{\aa}kansson and Pehrson, {P O}",

year = "1994",

language = "Dansk",

volume = "156",

pages = "3314--3318",

journal = "Ugeskr Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske Laegeforening",

number = "22",

}

TY - JOUR

T1 - Kontrolleret, klinisk afprøvning af isoprinosin til HIV-smittede. Resultater af en dansk/svensk multicenterundersøgelse. The Scandinavian Isoprinosine Study Group.

AU - Thorsen, S

AU - Pedersen, C

AU - Sandström, E

AU - Petersen, C S

AU - Norkrans, G

AU - Gerstoft, J

AU - Karlsson, A

AU - Christensen, K C

AU - Håkansson, C

AU - Pehrson, P O

PY - 1994

Y1 - 1994

N2 - The safety and efficacy of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported separately. Of 866 HIV-seropositive individuals randomized, 832 were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS. Within 48 weeks, 10/412 patients (2.4%) assigned isoprinosine and 27/420 (6.4%) assigned placebo progressed to AIDS (p = 0.005; odds ratio: 2.8, 95% CI: 1.3-6.2). Intention-to-treat analysis showed identical results. No severe adverse reactions or toxicities were observed. We conclude that HIV-infected individuals without AIDS may be safely and effectively treated with isoprinosine.

AB - The safety and efficacy of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported separately. Of 866 HIV-seropositive individuals randomized, 832 were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS. Within 48 weeks, 10/412 patients (2.4%) assigned isoprinosine and 27/420 (6.4%) assigned placebo progressed to AIDS (p = 0.005; odds ratio: 2.8, 95% CI: 1.3-6.2). Intention-to-treat analysis showed identical results. No severe adverse reactions or toxicities were observed. We conclude that HIV-infected individuals without AIDS may be safely and effectively treated with isoprinosine.

M3 - Tidsskriftartikel

SN - 1399-4174

VL - 156

SP - 3314

EP - 3318

JO - Ugeskr Laeger

JF - Ugeskr Laeger

IS - 22

ER -